Douglas Kerr - 12 Feb 2026 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Reporting relationship: Chief Medical Officer
Issuer ticker: DYN
Reported as of: 12 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Feb 2026, 17:10:59 UTC
Prior SEC filing: 05 Dec 2025
Next SEC filing: 06 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Ron Caponigro, Attorney-in-Fact

Key filing fact

Douglas Kerr filed Form 4 for Dyne Therapeutics, Inc. (DYN) on 17 Feb 2026.

Key facts

This page summarizes Douglas Kerr's Form 4 filing for Dyne Therapeutics, Inc. (DYN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Feb 2026, 17:10.

Change

Previous filing in this sequence was filed on 05 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001814189 Primary reporting owner

Kerr Douglas

Relationship: Chief Medical Officer
Address: C/O DYNE THERAPEUTICS, INC., 1560 TRAPELO ROAD, WALTHAM
Signature: /s/ Ron Caponigro, Attorney-in-Fact
Signature date: 17 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DYN transaction

Common Stock

Award

Transaction value: $0
Shares: +85,000
Change %: +97%
Price: $0.000000
Shares after: 172,510
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DYN transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +130,000
Change %
Price: $0.000000
Shares after: 130,000
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 130,000
Exercise price: $16.00
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Consists of shares of Common Stock issuable under 85,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on May 12, 2026.

Footnote F2

Includes 156,625 unvested RSUs.

Footnote F3

This option was granted on February 12, 2026. The shares underlying the option are scheduled to vest over four years in equal monthly installments through February 12, 2030.